Compare Novartis with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GSK PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GSK PHARMA NOVARTIS/
GSK PHARMA
 
P/E (TTM) x 718.5 217.5 330.4% View Chart
P/BV x 21.6 9.7 223.5% View Chart
Dividend Yield % 2.0 1.6 124.9%  

Financials

 NOVARTIS   GSK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-19
GSK PHARMA
Mar-19
NOVARTIS/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs9803,595 27.3%   
Low Rs6001,253 47.9%   
Sales per share (Unadj.) Rs198.7184.7 107.6%  
Earnings per share (Unadj.) Rs21.026.3 79.7%  
Cash flow per share (Unadj.) Rs22.329.2 76.3%  
Dividends per share (Unadj.) Rs10.0020.00 50.0%  
Dividend yield (eoy) %1.30.8 153.4%  
Book value per share (Unadj.) Rs307.5126.3 243.4%  
Shares outstanding (eoy) m24.69169.40 14.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.013.1 30.3%   
Avg P/E ratio x37.792.2 40.9%  
P/CF ratio (eoy) x35.583.1 42.7%  
Price / Book Value ratio x2.619.2 13.4%  
Dividend payout %47.776.1 62.7%   
Avg Mkt Cap Rs m19,508410,626 4.8%   
No. of employees `0000.65.0 11.7%   
Total wages/salary Rs m1,1715,372 21.8%   
Avg. sales/employee Rs Th8,445.46,306.7 133.9%   
Avg. wages/employee Rs Th2,015.71,083.1 186.1%   
Avg. net profit/employee Rs Th891.0898.0 99.2%   
INCOME DATA
Net Sales Rs m4,90731,281 15.7%  
Other income Rs m7831,023 76.5%   
Total revenues Rs m5,68932,304 17.6%   
Gross profit Rs m1236,009 2.0%  
Depreciation Rs m32486 6.5%   
Interest Rs m166 265.0%   
Profit before tax Rs m8586,540 13.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m3402,373 14.3%   
Profit after tax Rs m5184,454 11.6%  
Gross profit margin %2.519.2 13.0%  
Effective tax rate %39.636.3 109.3%   
Net profit margin %10.614.2 74.1%  
BALANCE SHEET DATA
Current assets Rs m8,05520,061 40.1%   
Current liabilities Rs m1,85014,543 12.7%   
Net working cap to sales %126.417.6 716.8%  
Current ratio x4.41.4 315.6%  
Inventory Days Days4557 79.3%  
Debtors Days Days3414 241.2%  
Net fixed assets Rs m15014,343 1.0%   
Share capital Rs m1231,694 7.3%   
"Free" reserves Rs m7,46919,704 37.9%   
Net worth Rs m7,59221,398 35.5%   
Long term debt Rs m02 0.0%   
Total assets Rs m9,82439,113 25.1%  
Interest coverage x54.91,091.0 5.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 62.4%   
Return on assets %5.411.4 47.6%  
Return on equity %6.820.8 32.8%  
Return on capital %11.531.9 36.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m58534 10.8%   
Fx outflow Rs m1,3267,091 18.7%   
Net fx Rs m-1,269-6,557 19.3%   
CASH FLOW
From Operations Rs m-1,9433,994 -48.6%  
From Investments Rs m2,742-1,433 -191.3%  
From Financial Activity Rs m-298-3,584 8.3%  
Net Cashflow Rs m501-1,023 -49.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 2.0 10.2 19.6%  
FIIs % 1.6 23.8 6.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 15.4 139.6%  
Shareholders   41,647 102,036 40.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   FULFORD INDIA  VENUS REMEDIES  CIPLA  WOCKHARDT  SUVEN LIFESCIENCES  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 1,375 Points; Nifty Ends Below 8,300 Mark(Closing)

Indian share markets witnessed selling pressure throughout the day and ended deep in the red with Sensex and Nifty witnessing a sharp fall during closing hours.

Related Views on News

IPCA LABS Surges by 6%; BSE HEALTHCARE Index Up 1.2% (Market Updates)

Mar 30, 2020 | Updated on Mar 30, 2020

IPCA LABS share price has surged by 6% and its current market price is Rs 1,317. The BSE HEALTHCARE is up by 1.2%. The top gainers in the BSE HEALTHCARE Index are IPCA LABS (up 5.8%) and ABBOTT INDIA (up 7.4%). The top losers are SANOFI INDIA (down 0.3%) and CAPLIN POINT (down 0.5%).

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

This Crorepati Stock Could Be the Best Vaccine for Your Portfolio Against Coronavirus(Profit Hunter)

Mar 17, 2020

If there is one stock I had to recommend you amid Coronavirus outbreak, this would be it.

If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)

Mar 19, 2020

Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.

Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)

Mar 19, 2020

The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...

A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)

Mar 25, 2020

I see a big opportunity to make fast profits on the horizon.

The Biggest Trading Opportunity of 2020 is Here...

Mar 26, 2020

India's #1 trader, Vijay Bhambwani, talks about a hugely profitable trading opportunity which you must know about today!

More

How to Trade the
Coronavirus Crash

Coronavirus Crash
Get this special report, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Mar 30, 2020 03:35 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS